Shots:

• Samsung to receive upfront- milestone and royalties on sales. 3SBio to get development & commercialization rights for Samsung’s biosimilars including SB8 (bevacizumab- Avastin) in China
• The focus of the agreement is for the expansion of Samsung’ biosimilar portfolio in China with its commercialization in the US- EU and Canada
• SB8 (bevacizumab- Avastin) is a mAb evaluated in P-III- indicated for the treatment of metastatic or recurrent non-squamous NSCLC

Ref: Samsung Bioepis | Image: Samsung Bioepis